Noveome is a clinical-stage biopharmaceutical company advancing ST266— a first-of-its-kind, multi-targeted secretome containing hundreds of biologically active proteins and other factors crucial to neuroprotection, the modulation of inflammation, cell recovery and healing.
ST266 contains physiologic levels of hundreds of active biomolecules, including growth factors and cytokines. These molecules modulate a host of biological pathways, including anti-inflammatory and neuroprotective mechanisms, critical to healing. Learn more about the science behind ST266 >
In both preclinical and clinical studies, ST266 has been shown to be well-tolerated with demonstrated biologic activity. We believe it holds significant promise to improve clinical outcomes in a range of complex diseases and conditions in categories as diverse as ophthalmology, neurology, dermatology and more. Explore our advancing pipeline >